October 10, 2012
1 min read

Cirrhotic patients coinfected with HIV, HCV less responsive to peg-IFN/RBV

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Treatment with pegylated interferon and ribavirin was less effective in patients with cirrhosis and coinfected with HIV and HCV than noncirrhotic patients in a recent study.

In a multicenter prospective cohort study, researchers evaluated 629 patients coinfected with HCV and HIV, including 175 with cirrhosis. All participants received treatment with pegylated interferon (peg-IFN) and ribavirin (RBV), and had undergone either a biopsy or liver stiffness measurement within 1 year of starting therapy. Follow-up included plasma HCV RNA measurement and assessment of adverse events, and occurred at least once every 4 weeks during the initial 24 weeks of treatment, then every 2 months until conclusion.

In intention-to-treat analysis, sustained virological response (SVR) occurred in 38.9% of noncirrhotic patients compared with 25.1% of those with cirrhosis (P=.001 for difference). Per-protocol analysis of 521 patients indicated significantly more incidence of SVR among those without cirrhosis (46% of patients compared with 33%, P=.007), and lack of cirrhosis was associated with SVR via multivariate analysis (adjusted OR=2.02; 95% CI, 1.1-3.4). Patients with cirrhosis also were significantly more likely to discontinue treatment due to adverse events than noncirrhotic patients (17% of patients vs. 8%, P=.001).

SVR was more common in cirrhotic patients with HCV genotype 2-3 (47% of patients) than those with genotype 1 (14%) or 4 (30%), and researchers observed a significant association between SVR and HCV genotype 1 or 4 (aOR=8.9, 2.7-29). Other factors predictive of SVR included baseline liver stiffness measurements of less than 30 kPa (aOR=4.1, 1.02-16.7) and a baseline HCV viral load of 600,000 IU/mL or less (aOR=6.0, 1.8-2.0) (95% CI for all).

“Although HIV-infected patients with compensated HCV-related cirrhosis are a hard-to-cure population, HCV therapy is a priority in these patients,” the researchers wrote. “Because of this, HCV therapy with peg-IFN plus RBV should be recommended to patients with genotype non-1 until more effective drugs are available. New drugs are needed to improve the efficacy of HCV therapy in HIV/HCV coinfected patients with compensated liver cirrhosis.”

Disclosure: See the study for a full list of relevant disclosures.